The number of M1 macrophages (CD68+/CD86+) increased significantly in the CKD model group compared to the sham group (P < 0.001), while decreased after ATL-III treatment (P < 0.001) (Figures S1a and S1d). The gene discussed is CD86; the disease is chronic kidney disease.